Clinical Takeaway
In a small randomized crossover trial, autistic children aged 5 to 12 received weight-based CBD oil dosing over 12-week periods, allowing researchers to directly compare CBD against placebo within the same participants. This study design provides a more controlled look at whether oral CBD with terpenes can meaningfully affect social behavior, anxiety, and parenting stress. Results from this trial add to a growing but still limited evidence base on CBD as a pharmacological option in pediatric autism management.
#28 Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial.
Citation: Parrella Nina-Francesca et al.. Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial.. Autism research : official journal of the International Society for Autism Research. 2026. PMID: 41452412.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 3 Human: 1 Risk: -2
This RCT provides rigorous clinical evidence on CBD’s efficacy for core autism-related symptoms including social difficulties and anxiety, which currently lack FDA-approved pharmacological treatments beyond symptom management. The study’s design addressing parental stress alongside child outcomes captures a clinically relevant outcome, as caregiver burden significantly impacts family functioning and treatment adherence in pediatric autism. These findings could inform clinical decision-making regarding non-intoxicating cannabinoid use as an adjunctive therapeutic option for children with autism who have inadequate response to conventional interventions.
Quality Gate Alerts:
- Preclinical only
Abstract: Cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, has garnered increasing attention as a potential pharmacological therapeutic for autism. We conducted a randomized, double-blind, placebo-controlled, crossover trial to understand whether oral CBD oil containing terpenes can improve outcomes in autistic children. Twenty-nine children (18 male), aged 5 to 12 years (M = 9.62 years, SD = 2.05), diagnosed with autism spectrum disorder, completed the study. Participants received weight-based dosing of CBD oil (10 mg/kg/day) or matched placebo oil over two 12-week intervention periods (crossover), separated by an 8-week washout period. Outcome measures included the Social Responsiveness Scale-2 (SRS-2; primary outcome), PROMIS Social Relating, Anxiety, and Sleep, Developmental Behavior Checklist-2 (DBC-2), Vineland-3, and Autism Parenting Stress Index (APSI; secondary outcomes). There was no significant effect observed for the primary outcome measure (SRS-2) for CBD oil relative to placebo oil after 12 weeks (β = -11.15, SE = 7.19, p = 0.125). Significant improvements were observed in secondary measures of social functioning, including DBC-2 Social Relating (β = -2.35, SE = 0.92, p(adj) = 0.024), as well as reduced anxiety on the DBC-2 subscale (β = -3.20, SE = 0.94, p(adj) = 0.002), and lower parental stress (APSI; β = -4.63, SE = 2.26, p(adj) = 0.044). No differences were detected on Vineland-3 adaptive functioning (ABC: β = 2.06, SE = 2.67, p(adj) = 1.000), and domain scores were not significant. Safety and tolerability data indicated that two children experienced gastrointestinal discomfort while taking CBD. Findings from this pilot trial suggest that while CBD combined with terpenes did not improve the primary outcome of social responsiveness, it may hold potential in addressing certain autism-related difficulties, particularly anxiety and social relating. Further research with larger sample sizes is needed to fully evaluate the efficacy
🧠 This small randomized crossover trial suggests CBD may offer modest benefits for social engagement, anxiety, and parental stress in autistic children, though several limitations warrant cautious interpretation. The sample size of 29 participants is relatively modest, the study duration appears brief, and the use of a terpene-containing preparation rather than isolated CBD complicates attribution of effects to CBD alone. Important confounders including baseline anxiety severity, concurrent medications, and potential expectancy effects in parents assessing their children’s behavior are not fully addressed. Despite these caveats, the rigorous double-blind design and focus on parent-reported functional outcomes rather than just symptom checklists make this a meaningful contribution to an understudied population. Clinicians considering CBD for autistic children with comorbid anxiety might discuss this evidence with families while emphasizing the need for larger, longer-term studies and careful monitoring for drug interactions, especially in children already on psychotropic or seizure medications.